These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 12108434)
21. Safety of pharmacotherapy of osteoporosis in cardiology patients. Zapolski T; WysokiĆski A Cardiol J; 2010; 17(4):335-43. PubMed ID: 20690088 [TBL] [Abstract][Full Text] [Related]
22. European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition. Atar D Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):3-4. PubMed ID: 28062654 [No Abstract] [Full Text] [Related]
23. Emerging role of NET inhibitors in cardiovascular diseases. Jayaseelan VP; Paramasivam A Hypertens Res; 2020 Dec; 43(12):1459-1461. PubMed ID: 32733104 [No Abstract] [Full Text] [Related]
24. Gp IIb/IIIa antagonists. Summary and table. Coleman SG; Duff R Drugs R D; 1999 May; 1(5):371-3. PubMed ID: 10566066 [No Abstract] [Full Text] [Related]
25. Cardiovascular pharmacology in the post-blockbuster era. Brandes RP Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904 [No Abstract] [Full Text] [Related]
26. Emerging Cardiovascular Therapeutics. Cambridge, MA, USA, June 10-11, 2003. Zavoico GB Cardiovasc Drug Rev; 2003; 21(3):246-53. PubMed ID: 14582482 [No Abstract] [Full Text] [Related]
27. Cardiovascular pharmacotherapy-2015 was a good year. Lewis BS Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):209-11. PubMed ID: 27600902 [No Abstract] [Full Text] [Related]
28. Pharmacology of cardiac and vascular remodeling. A satellite symposium of the 11th World Congress of the International Union of Pharmacology (IUPHAR). Maastricht, The Netherlands, July 8-10, 1990. Basic Res Cardiol; 1991; 86 Suppl 1():1-187. PubMed ID: 2036088 [No Abstract] [Full Text] [Related]
31. Autophagy in cardiovascular biology. Lavandero S; Chiong M; Rothermel BA; Hill JA J Clin Invest; 2015 Jan; 125(1):55-64. PubMed ID: 25654551 [TBL] [Abstract][Full Text] [Related]
32. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Balakumar P; Dhanaraj SA Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531 [TBL] [Abstract][Full Text] [Related]
33. Old and new drugs in cardiovascular pharmacotherapy. Agewall S Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):1-2. PubMed ID: 30615170 [No Abstract] [Full Text] [Related]
38. Cardiovascular pharmacotherapy in patients with Marfan syndrome. Yetman AT Am J Cardiovasc Drugs; 2007; 7(2):117-26. PubMed ID: 17503882 [TBL] [Abstract][Full Text] [Related]
39. Achieving current goals in prevention and treatment of vascular disease: an update. Catapano AL; Elisaf MS; Florentin M; Mikhailidis DP; Kostapanos MS Curr Pharm Des; 2013; 19(21):3749-52. PubMed ID: 23286439 [No Abstract] [Full Text] [Related]
40. The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted! Agewall S Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):207-8. PubMed ID: 27600901 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]